Vimta Labs Limited

Equities

VIMTALABS

INE579C01029

Biotechnology & Medical Research

Delayed Bombay S.E. Other stock markets 01:20:30 2024-07-10 am EDT			5-day change	1st Jan Change
504.8 ^INR	-2.30%		+5.05%	+25.22%

May. 21	Vimta Labs Limited Provides Revenue Guidance for the Fiscal Year 2026	CI
May. 21	Transcript : Vimta Labs Limited, Q4 2024 Earnings Call, May 21, 2024

Vimta Labs Limited Recommends Dividend for the Financial Year 2023-2024

May 18, 2024 at 06:20 am EDT

Vimta Labs Limited at its board meeting held on May 18, 2024, recommended Dividend of INR 2 per share with face value of INR 2 each for the financial year 2023-2024, subject to approval of shareholders in their upcoming Annual General Meeting.

Latest news about Vimta Labs Limited

Vimta Labs Limited Provides Revenue Guidance for the Fiscal Year 2026	May. 21	CI
Transcript : Vimta Labs Limited, Q4 2024 Earnings Call, May 21, 2024	May. 21
Vimta Labs Limited Recommends Dividend for the Financial Year 2023-2024	May. 18	CI
Vimta Labs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 18	CI
Vimta Labs Limited Receives Grant in Aid for Upgrading of Food Testing Laboratory At Vimta Life Sciences Facility Plot No.5, Mn Science Technology Park, Genome Valley, Shameerpet, Hyderabad, Telangana	Mar. 02	CI
Transcript : Vimta Labs Limited, Q3 2024 Earnings Call, Feb 01, 2024	Feb. 01
Vimta Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 31	CI
Transcript : Vimta Labs Limited, Q2 2024 Earnings Call, Oct 30, 2023	23-10-30
Vimta Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-30	CI
Transcript : Vimta Labs Limited, Q1 2024 Earnings Call, Jul 31, 2023	23-07-31
Vimta Labs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-28	CI
CARE Gives A Rating to Vimta Labs' Long-term Bank Financing; Outlook Stable	23-07-12	MT
Vimta Labs Limited Declares Dividend for the Financial Year Ended March 31, 2023	23-06-28	CI
Transcript : Vimta Labs Limited, Q4 2023 Earnings Call, May 05, 2023	23-05-05
Vimta Labs Names New Executive Chairman	23-05-03	MT
Vimta Labs Limited Recommends Dividend for the Financial Year 2022-2023	23-05-03	CI
Vimta Labs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-03	CI
Transcript : Vimta Labs Limited, Q3 2023 Earnings Call, Jan 30, 2023	23-01-30
Vimta Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-01-27	CI
Brickwork Ratings Affirms A Rating on Vimta Labs' Bank Loans; Outlook Stable	22-11-30	MT
Transcript : Vimta Labs Limited, Q2 2023 Earnings Call, Oct 28, 2022	22-10-28
Vimta Labs Logs Rise in Fiscal Q2 Consolidated Profit	22-10-27	MT
Vimta Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-10-27	CI
Vimta Labs Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-07-25	CI
Vimta Labs Limited Approves Dividend for the Financial Year Ended March 31, 2022, Payable on June 30, 2022	22-06-25	CI

Chart Vimta Labs Limited

Duration

Period

More charts

Company Profile

Vimta Labs Limited is engaged in the business of contract research and testing organization. The Company is engaged in providing a range of services to biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, power, cement, oil and gas, ores and minerals, infrastructure and many other industries, government organizations as well as other industry participants. Its services include Drug discovery, development, and drug life cycle management support services; Preclinical research and testing services for medical device companies; Contract research and testing for agrochemical and specialty chemical companies; and Food testing and analytical development services to support manufacturers, processors, farmers, and retailers; Clinical diagnostics services to patients, clinicians, and hospitals, and environmental regulatory services such as impact assessments and post project monitoring, to various industries, such as power and infrastructure.

Sector

Biotechnology & Medical Research

Calendar

2024-07-10 - Détachement de for final dividend

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
VIMTA LABS LIMITED	+25.22%	137M
EXACT SCIENCES CORPORATION	-40.40%	8.14B
GUARDANT HEALTH, INC.	+2.22%	3.38B
IOVANCE BIOTHERAPEUTICS, INC.	-7.26%	2.11B
BGI GENOMICS CO., LTD.	-28.23%	1.81B
VERACYTE, INC.	-22.68%	1.63B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+15.57%	1.01B
CAREDX, INC	+21.83%	763M
SEEGENE, INC.	-9.61%	690M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-27.76%	522M

Bio Diagnostics & Testing